Opus Genetics, Inc.
Opus Genetics, Inc. (Nasdaq: IRD) is a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases and other treatments for ophthalmic disorders. Its pipeline includes seven adeno-associated virus gene therapy programs targeting mutations associated with conditions such as Leber… From the company’s description.
Over the twelve months to Jun 30, 2026, Opus Genetics, Inc. reported revenue of $9.86M, down 36.1% from a year earlier, and a net loss of $107.61M. Its operating margin was −513.5%, and operations used $40.67M in cash. In fiscal 2025, it reported revenue of $14.20M, up 29.1% from fiscal 2024, and a net loss of $49.59M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Opus Genetics, Inc. does
In the company’s own words
Opus Genetics, Inc. (Nasdaq: IRD) is a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases and other treatments for ophthalmic disorders. Its pipeline includes seven adeno-associated virus gene therapy programs targeting mutations associated with conditions such as Leber congenital amaurosis, bestrophinopathy and retinitis pigmentosa, alongside phentolamine ophthalmic solution 0.75%, a small-molecule eye drop. The gene therapies are designed as one-time treatments delivered by subretinal injection; the company’s most advanced programs target LCA5 and BEST1. Phentolamine is FDA-approved as RYZUMVI for reversing pharmacologically induced pupil dilation and is also being developed for presbyopia and low-light visual disturbances after refractive surgery. Viatris holds an exclusive license to develop and commercialize phentolamine in most global markets and is responsible for commercialization. Opus also has APX3330, a small-molecule candidate studied for diabetic retinopathy, for which it is seeking a strategic partner. Founded as Ocuphire Pharma in 2018, the company acquired the private Opus Genetics in 2024 and adopted its name. Its website is https://www.opusgenetics.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- DURHAM, NC
- Fiscal year end
- December
- CIK
- 1228627
- SIC
- 2834
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Opus Genetics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Opus Genetics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Opus Genetics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Opus Genetics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Opus Genetics, Inc.'s last four quarterly filings that the numbers alone won't show?”